Complication and Sequelae of COVID-19: What Should We Pay Attention to in the Post-Epidemic Era

Keda Yang†, Guangfu Wen†, Jinpeng Wang†, Siming Zhou†, Wacili Da†, Yan Meng†, Yuchuan Xue* and Lin Tao*

1 Department of Orthopedics, First Hospital of China Medical University, Shenyang, China, 2 Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China, 3 The First Department of Clinical Medicine, China Medical University, Shenyang, China

COVID-19 is widespread worldwide and seriously affects the daily life and health of humans. Countries around the world are taking necessary measures to curb the spread. However, COVID-19 patients often have at least one organ complication and sequelae in addition to respiratory symptoms. Controlling the epidemic is only a phased victory, and the complication and sequelae of COVID-19 will need more attention in the post-epidemic era. We collected general information from over 1000 articles published in 2020 after the COVID-19 outbreak and systematically analyzed the complication and sequelae associated with eight major systems in COVID-19 patients caused by ACE2 intervention in the RAS regulatory axis. The autoimmune response induced by 2019-nCoV attacks and damages the normal tissues and organs of the body. Our research will help medical workers worldwide address COVID-19 complication and sequelae.

Keywords: COVID-19, complication, sequelae, eight systems, bibliometric analysis, Web of Science

INTRODUCTION

COVID-19 was one of the most concerning issues in 2020. Coronavirus threatens the life and health of humans (1). In addition, no country around the world has been completely spared. At present, humans have not truly controlled the spread of 2019-nCoV, and due to the alteration in climate, a second epidemic has appeared. According to the data of the World Health Organization (WHO), the global number of COVID-19 cases has reached over 130 million, with no sign of weakening. Our previous studies indicated that 2019-nCoV and SARS share a very similar viral gene sequence, origin, and intracellular receptor, ACE2 (2). People infected with 2019-nCoV will have symptoms of varying degrees ranging from a fever or a slight cough to pneumonia and even death (3). Most patients are asymptomatic or have mild cases, and even patients with more severe symptoms can recover with the help of medical treatment.

A prominent problem in the post-epidemic era is the complication and sequelae of COVID-19. All systems of the human body are at risk of being attacked by COVID-19 (4). A number of studies have demonstrated that patients with 2019-nCoV have at least one organ complication and sequelae in addition to respiratory symptoms even if the symptoms are mild (5, 6). More than three-quarters of COVID-19 patients reported having at least one sequelae six months after the onset of the disease (7). Although COVID-19 is an infectious disease characterized by pneumonia, complication...
affecting the cardiovascular system are the most serious and fatal. In clinical testing of COVID-19 patients, it was found that the level of angiotensin converting enzyme (ACE) was extremely low (8). A decline in ACE increases the risk of hypertension, myocarditis, and even heart failure (9–11). Meanwhile, the impact of 2019-nCoV on the nervous system is also very serious. A study indicated that nearly 40% of COVID-19 patients showed neurological symptoms (12). Severe encephalitis causes cerebral parenchymal disease and induces brain death (13). In addition, there is a certain impact of 2019-nCoV on the digestive, urinary and endocrine systems (14–16).

Comparative genomics of different strains of 2019-nCoV around the world have been fully analyzed (17–19). As more and more people in various countries are vaccinated, it is believed that the epidemic will be brought under control soon. The prevention of and interventions for patients’ complication and sequelae will be the focus in the post-epidemic era.

Bibliometric analysis is an interdisciplinary science which could obtain the objective and quantifiable data of certain field (20). It could provide research hotspots and directions in a specific field by analyzing various parameters of published works and foster collaborative transdisciplinary research (21, 22). Therefore, this study aimed to explore the research status and to predict future trends of COVID-19 complication and sequelae by using original research bibliometric analysis. We believe our study will attract the attention of medical workers and researchers worldwide and enrich the process of COVID-19 prevention and management.

MATERIALS AND METHODS

Search Strategy and Inclusion Criteria
The relevant articles were retrieved from the Web of Science core collection database according to the indexes COVID-19 and complication or sequelae on December 30, 2020. The time range of retrieval covered all years, that is, from the year that the database was created to the search date. There were a total of 1169 publications, and their types included reviews, articles, early access, editorial materials, and letters. Then, we established the inclusion criteria and screened the articles against the inclusion criteria: (a) published in English, (b) involved COVID-19 research, and (c) focused on a discussion of complication and sequelae (Supplementary Figure 1).

Data Extraction
The above operations were performed by two reviewers independently, and a third reviewer helped them build a consensus when disagreements occurred. The general information of these articles was listed, including the title, publication date, name of the first author and corresponding author, geographic origin, publication journal, publication institution, research theme, and journal impact factor.

Bibliometric Analysis
The extracted information of these articles was imported into the Online Analysis Platform of Literature Metrology (http://bibliometric.com/) and integrated according to their characteristics. CiteSpace V5.5.R1 SE, 64 bit (Drexel University, Philadelphia, PA, USA) and VOSviewer (Leiden University, Leiden, the Netherlands) were used to visualize the network of this information, such as authors and counties, institutions, and journals (23, 24). We also identified research trends and predicted evolutionary directions in terms of high-frequency keywords on CiteSpace. The approach is described in detail in our previous study on COVID-19 and the SARS and MERS coronaviruses (2).

RESULTS

Most Active Countries and Institutions
The top ten most active countries according to the number of publications each year are shown in Figure 1. These ten countries all have highly developed economies and dense population flows, resulting in wide and rapid spread of the epidemic. Unsurprisingly, America and European countries (especially the UK) were the predominant countries. China also contributed a large number of articles due to the early
detection of the coronavirus. International cooperation was dominated by the United States, Italy, and China, which was consistent with the ranking by the number of publishing articles (Figure 2). Based on the number of articles, we listed the top 10 institutions (Figure 3). Two universities from Wuhan, China, ranked in the top two. Huazhong University of Science and Technology ranked first with 78 articles, and Wuhan University ranked second with 45 articles. Columbia University, the Mayo Clinic and the University of Paris ranked third, fourth and fifth, with 37, 32 and 27 articles, respectively. Besides, Harvard Medical School, the National and Kapodistrian University of Athens, the University of Toronto, the University of Milan, and

**Most Active Authors and Journals**

We counted the authors who were the first or corresponding authors of these articles and ranked them in descending order by the published article count for the top ten authors (Table 1). Seven of these authors were from China. Zhang, Y published the most articles (n=8), one as the first author. Liu, H ranked second with five articles. Each of the remaining eight authors published 4 articles each: Wang, L, Connors, JM, Thachil, J, Khan, S, Liu, W, Li, XY, Yang, F and Chen, T. The top ten co-cited authors are

![FIGURE 2](image) The distribution of countries/regions. The cooperation of countries/regions.
listed in Figure 4 in descending order of article count. CiteSpace was used to reveal the network of these co-cited authors (Figure 5). All of these authors participated in over 100 articles and in over 200 articles of the top five authors. They were Huang CL (n=366), Zhou F (n=298), Wang DW (n=289), Guan W (n=265) and Chen NS (n=214).

The top ten journals are listed in descending order by the number of published articles (Table 2). The Journal of Medical Virology (IF: 2.327) published 14 articles, which was the highest number and accounted for 14.4% of the total 97 articles published by the ten journals. The second ranked journal was Journal of Clinical Medicine (IF: 4.241), which published 12 articles. Ten articles were published in each of the next four journals. They were Journal of Thrombosis and Haemostasis (IF: 5.824), Journal of Stroke and Cerebrovascular Disease (IF: 2.136), Frontiers in Neurology (IF: 4.003) and Diabetes Research and Clinical Care (IF: 5.602). The total citation count of Journal of Thrombosis and Haemostasis (IF: 5.824) was 85, belonging to Q1 according to the quartile in category which represents the credibility and recognition of the journal. In addition, of all these journals, Critical Care has the highest impact factors (IF: 9.097), while Frontiers in Immunology ranks the second (IF: 7.561).

### Research Hotspots

A total of 82 keywords were extracted and are listed in Table 3. The number of occurrences of keywords ranged from 69 to 3972 times. Through VOSviewer analysis, these items were classified into 5 clusters, which are shown in Figures 6A, B. Each cluster had a common theme: cluster 1 (23 items, in red, treatment), cluster 2 (19 items, in green, clinical manifestation), cluster 3 (16 items, in blue, risk factors), cluster 4 (12 items, in yellow, morbidity), and cluster 5 (12 items, in purple, diagnosis). The top five keywords of each cluster are listed as follows, and the number of occurrences is indicated:

Cluster 1: COVID (3972), Complication (1196), SARS cov (1028), Infection (970), Disease (761)

Cluster 2: Patient (3249), Study (685), Level (280), Time (231), Admission (227).

Cluster 3: Outcome (417), Mortality (363), Death (237), Age (226), Person (190).

Cluster 4: Pandemic (619), Risk (490), Management (314), Care (281), Surgery (234).

Cluster 5: Case (555), Symptom (352), Data (294), Pneumonia (216), Report (193).

---

**TABLE 1** | The top ten authors contributed to the research about COVID-19 complication and sequelae sorted by total number of articles.

| Rank | Author       | Article counts | First author counts | Corresponding author counts |
|------|--------------|----------------|---------------------|----------------------------|
| 1    | Zhang, Y     | 8              | 1                   | 0                          |
| 2    | Liu, H       | 5              | 1                   | 0                          |
| 3    | Wang, L      | 4              | 1                   | 1                          |
| 4    | Connors, JM  | 4              | 1                   | 1                          |
| 5    | Thachill, J  | 4              | 2                   | 1                          |
| 6    | Khan, S      | 4              | 1                   | 0                          |
| 7    | Liu, W       | 4              | 1                   | 1                          |
| 8    | Li, XY       | 4              | 2                   | 0                          |
| 9    | Yang, F      | 4              | 2                   | 0                          |
| 10   | Chen, T      | 4              | 1                   | 0                          |
DISCUSSION

So far, 2019-nCoV has infected one hundred and thirty million people and affected the lives of billions of people. As the understanding of COVID-19 patients continues to develop, clinicians have gradually realized the dangers of the sequelae and complication that COVID-19 patients have. Early detection of possible complication and sequelae of each system will improve clinical outcomes and reduce their incidence. Laboratory and clinical data will be crucial to clarify the pathophysiology and potential damage of 2019-nCoV to various systems. Finally, the various system evaluations of patients after recovery are critical to understanding the natural history of 2019-nCoV in various systems and monitoring potential system sequelae. Therefore, we took the eight major systems as the entry point and analyzed in detail the morbidity and pathogenesis of the possible complication and sequelae of each system of COVID-19 patients (Supplementary Figure 2).

FIGURE 4 | The distribution of authors involved in COVID-19 complication and sequelae research. The article counts of the top ten co-cited authors.

FIGURE 5 | The distribution of authors involved in COVID-19 complication and sequelae research. The network map of co-cited authors.
Respiratory Sequelae
The respiratory system is the primary target for attack by 2019-nCoV. Pathological changes occurred in the pulmonary parenchyma, pulmonary vascular endothelium, and alveoli of patients infected with COVID-19 (25). There are case reports that the alternations in pulmonary parenchyma caused by 2019-nCoV could induce the occurrence of pneumothorax, leading to severe vasculitis and endotheliitis (26). In the tissue section observations of the lung tissue of patients who died from COVID-19, it was found that the alveoli were destroyed and infiltrated by a large number of inflammatory cells, and the pulmonary microvascular was accompanied by a large number of thromboses (27, 28). Additionally, many patients recovering from COVID-19 still have a cough and shortness of breath after being cured, and severe cases can have extensive fibrosis of the lungs, resulting in severe dyspnea (29). The above alternations would cause an imbalance of the ventilatory flow ratio, and there is no evidence that these pathological alterations are reversible. Therefore, patients infected with COVID-19 are impacted with severe pulmonary fibrosis and are still at risk after their nucleic acid test turns negative.

Cardiovascular Complication
Similar to other respiratory infections, pre-existing cardiovascular disease or risk factors increase susceptibility to COVID-19 (30). Meanwhile, the mortality of patients with cardiovascular disease is relatively higher (31). The cardiovascular diseases of patients infected with 2019-nCoV worsen significantly, and it can even cause new cardiovascular complication. A study from Wuhan, China showed that nearly 20% of patients infected with 2019-nCoV suffered cardiovascular damage and the patients’ conditions would worsen if their IL-6 was elevated (32, 33). The most serious cardiovascular complication of COVID-19 patients is myocarditis, which is most commonly defined as an elevation of hypersensitivity cardiac troponin I (cTnI) above the 99th percentile of the upper reference limit (34). The onset of acute myocarditis results in ischemia and hypoxia and increases the risk of death if it exceeds the bearing capacity of the body (35, 36). In addition, both tachy- and brady-arrhythmias are known to occur in COVID-19 patients (37). However, no study has described the incidence of ST-segment elevation myocardial infarction in COVID-19, but it appears to be low. Angiotensin converting enzyme 2 (ACE2) plays an essential role in the development of cardiovascular diseases (38). High expression of ACE2 in COVID-19 patients lead to an imbalance of renin-angiotensin-aldosterone system (RAAS), which participates in the regulation of electrolytes and blood flow (38, 39). Excessive contraction of blood vessels and acceleration of blood flow increased the risk of hypertension and thrombosis (40). In addition, elevated pressure in the peripheral blood increases the afterload on the heart and consequently causes organic pathological alterations of cardiac dilatational hypertrophy (41). A study by Frankfurt University Hospital showed that 78 out of 100 survivors of COVID-19 had cardiovascular abnormalities, and 60 of them still had signs of persistent myocardial inflammation more than two months after the diagnosis (42).

Neurological Complication
Neurological symptoms are also common in patients infected with 2019-nCoV (43, 44). Nearly forty percent of patients have neurological manifestations (12). Most of these effects are seizures, delirium, and unconsciousness (45–47). A British study analyzed 153 patients with clinical syndromes related to COVID-19 pneumonia. Many of the patients suffered from new-onset psychosis, neurocognitive syndromes or affective disorders, and changes in mental status, which usually occurred in relatively young patients. Some showed symptoms associated with Guillain-Barre syndrome (48–50). When this virus infects the brain, viral encephalitis and purulent lesions increase the difficulty of treatment and caused sequelae after treatment (51). In addition, the most dangerous condition was that the virus would induce paralysis of the respiratory center, causing apnea and threatening the patient’s life if it invaded the medulla oblongata and pons (44). Recent studies indicated that 2019-nCoV can break through the blood-brain barrier and invade the brain, mainly through the nasal cavity and intestines and the virus has been detected in cerebrospinal fluid (52–54). In addition, it was found in the clinical examination of patients with neurological symptoms that almost all patients on imaging had brain bleeding to different degrees (55). Cranial nerve injury leads to a loss of smell, temporary loss of consciousness, and even stroke (56–58). Local hypoxemia induced by cerebral circulation disorders can lead to permanent alterations of the brain (12).

Digestive Complication
The clinical findings indicated that gastrointestinal reactions and liver dysfunction appeared in patients with COVID-19 (59, 60). Inappetence, vomiting, diarrhea and indigestion occurred in the patients. A meta-analysis of patient data from multiple countries
### TABLE 3 | The analytic consequence of 82 keywords with from 69 to 3972 occurrence times.

| Keywords                                | cluster | Links | Total link strength | Occurrences | Average publishing years | Average citations |
|-----------------------------------------|---------|-------|---------------------|-------------|--------------------------|-------------------|
| Ace2                                    | 1       | 77    | 2950                | 82          | 20.3049                  | 2.1854            |
| Acute Respiratory Distress Syndrome     | 1       | 81    | 5067                | 127         | 26.063                   | 2.8052            |
| Addiction                               | 1       | 81    | 3290                | 89          | 3.7528                   | 0.4039            |
| Admission                               | 2       | 81    | 11509               | 227         | 10.6123                  | 1.1422            |
| Age                                     | 3       | 81    | 11724               | 226         | 17.2522                  | 1.8612            |
| April                                   | 5       | 81    | 6073                | 121         | 6.5473                   | 0.6831            |
| Ards                                    | 1       | 77    | 4060                | 102         | 12.5294                  | 1.3486            |
| Article                                 | 1       | 81    | 4303                | 122         | 4.4016                   | 0.4738            |
| Association                             | 3       | 81    | 5055                | 93          | 30.5484                  | 3.288             |
| Care                                    | 4       | 81    | 9407                | 281         | 5.0641                   | 0.5468            |
| Case                                    | 5       | 81    | 21451               | 555         | 12.6649                  | 1.364             |
| China                                   | 2       | 81    | 7650                | 172         | 25.4076                  | 2.7348            |
| Clinical Character                      | 2       | 81    | 4076                | 77          | 32.6104                  | 3.5099            |
| Comorbidity                             | 3       | 81    | 8449                | 178         | 19.7584                  | 2.1349            |
| Complication                            | 1       | 81    | 43447               | 1196        | 9.8712                   | 1.0629            |
| Coronavirus                             | 1       | 81    | 7972                | 232         | 15.3578                  | 1.6551            |
| Coronavirus Disease                     | 1       | 81    | 19632               | 498         | 18.998                   | 2.0448            |
| Country                                 | 4       | 81    | 4056                | 108         | 10                      | 1.0763            |
| Covid                                   | 1       | 81    | 136572              | 3972        | 10.1803                  | 1.0658            |
| Cytokine Storm                          | 1       | 78    | 2548                | 81          | 5.9012                   | 0.6352            |
| Data                                    | 5       | 81    | 14373               | 294         | 15.0272                  | 1.6174            |
| Day                                     | 2       | 81    | 10904               | 215         | 17.8326                  | 1.9193            |
| Death                                   | 3       | 81    | 11838               | 237         | 16.8608                  | 1.8148            |
| December                                | 2       | 81    | 3254                | 81          | 21.679                   | 2.3333            |
| Diabetes                                | 3       | 81    | 7891                | 173         | 6.948                    | 0.7478            |
| Diabetes                                | 3       | 79    | 5983                | 89          | 6.1461                   | 0.6615            |
| Diagnosis                               | 5       | 81    | 6494                | 157         | 8.9873                   | 0.9673            |
| Disease                                 | 1       | 81    | 29238               | 761         | 11.2943                  | 1.2156            |
| Drug                                    | 1       | 81    | 5427                | 144         | 8.0764                   | 0.8693            |
| Effect                                  | 1       | 81    | 8792                | 222         | 9.4324                   | 1.0152            |
| Evidence                                | 1       | 81    | 8986                | 241         | 11.1452                  | 1.1996            |
| Fever                                   | 5       | 81    | 4561                | 108         | 18.3796                  | 1.9782            |
| Group                                   | 2       | 81    | 11325               | 222         | 11.8288                  | 1.2732            |
| Higher Risk                             | 3       | 81    | 3236                | 73          | 17.8356                  | 1.9197            |
| Hospital                                | 2       | 80    | 9604                | 180         | 16.0056                  | 1.7254            |
| Hospitalization                         | 2       | 81    | 4762                | 96          | 24.3789                  | 2.6239            |
| Hypertension                            | 3       | 81    | 5960                | 111         | 21.8739                  | 2.3543            |
| Icu                                     | 2       | 79    | 3409                | 69          | 11.2174                  | 1.2073            |
| Impact                                  | 4       | 81    | 6252                | 164         | 10.7988                  | 1.1683            |
| Incidence                               | 2       | 81    | 5196                | 102         | 10.3922                  | 1.1185            |
| Individual                              | 3       | 81    | 3734                | 97          | 6.5773                   | 0.713             |
| Infection                               | 1       | 81    | 36677               | 970         | 10.5299                  | 1.1339            |
| Intensive Care Unit                     | 2       | 81    | 5042                | 109         | 10.7339                  | 1.1598            |
| Level                                   | 2       | 81    | 11449               | 280         | 28.3036                  | 3.0464            |
| Management                              | 4       | 81    | 11873               | 314         | 6.9841                   | 0.7548            |
| March                                   | 2       | 80    | 7029                | 142         | 8.0845                   | 0.8701            |
| Mortality                               | 3       | 81    | 18373               | 363         | 18.1488                  | 1.9547            |
| Need                                    | 4       | 81    | 4283                | 126         | 7.5635                   | 0.8141            |
| Number                                  | 4       | 81    | 7299                | 170         | 8.6294                   | 0.9317            |
| Obesity                                 | 3       | 80    | 4120                | 89          | 4.382                    | 0.4716            |
| Outbreak                                | 4       | 81    | 7508                | 162         | 20.1605                  | 2.1699            |
| Outcome                                 | 3       | 81    | 20998               | 417         | 16.8585                  | 1.8157            |
| Pandemic                                | 4       | 81    | 21700               | 619         | 5.2763                   | 0.5687            |
| Patient                                 | 2       | 81    | 125336              | 3249        | 16.9471                  | 1.8251            |
| Person                                  | 3       | 81    | 7936                | 190         | 5.5632                   | 0.5988            |
| Pneumonia                               | 5       | 81    | 8778                | 216         | 13.3704                  | 1.4391            |
| Pregnancy                               | 5       | 80    | 5430                | 114         | 19.5068                  | 2.0998            |
| Pregnant Woman                          | 5       | 79    | 4581                | 102         | 13.4314                  | 1.4456            |
| Recommendation                         | 4       | 80    | 4012                | 116         | 7.9224                   | 0.8527            |
| Report                                  | 5       | 81    | 7448                | 193         | 14.399                   | 1.5523            |
| Review                                  | 1       | 81    | 12982               | 327         | 7.2263                   | 0.7778            |
| Risk                                    | 4       | 81    | 18852               | 490         | 9.4224                   | 1.0182            |

(Continued)
| Keywords                                                                 | cluster | Links | Total link strength | Occurrences | Average publishing years | Average citations |
|------------------------------------------------------------------------|---------|-------|---------------------|-------------|--------------------------|------------------|
| Risk Factor                                                            | 3       | 81    | 7551                | 152         | 9.0724                   | 0.9765           |
| Role                                                                   | 1       | 81    | 5383                | 171         | 3.6433                   | 0.3921           |
| Sars Cov                                                               | 1       | 81    | 36063               | 1028        | 9.2091                   | 0.9926           |
| Severe Acute Respiratory Syndrome Coronavirus                          | 1       | 81    | 8304                | 232         | 13.431                   | 1.4477           |
| Severe Covid                                                           | 1       | 81    | 4092                | 103         | 6.0485                   | 0.651            |
| Severity                                                               | 3       | 81    | 6534                | 139         | 11.0504                  | 1.1894           |
| study                                                                  | 2       | 81    | 32035               | 685         | 12.8307                  | 1.381            |
| surgery                                                                | 4       | 78    | 10541               | 234         | 7.6325                   | 0.8215           |
| symptom                                                                | 5       | 81    | 13853               | 352         | 12.0504                  | 1.1974           |
| Time                                                                   | 2       | 81    | 9549                | 231         | 13.8701                  | 1.4971           |
| total                                                                   | 2       | 80    | 3852                | 77          | 16.6883                  | 1.7962           |
| treatment                                                              | 1       | 81    | 19442               | 521         | 8.3129                   | 0.8985           |
| Type                                                                   | 3       | 81    | 5512                | 96          | 10.0417                  | 1.0808           |
| use                                                                    | 1       | 81    | 5959                | 154         | 9.3247                   | 1.1068           |
| virus                                                                  | 1       | 81    | 8190                | 234         | 9.3761                   | 1.1092           |
| week                                                                   | 5       | 79    | 3737                | 74          | 26.8649                  | 2.8915           |
| world                                                                  | 4       | 81    | 2941                | 84          | 6.6071                   | 0.717            |
| Wuhan                                                                  | 2       | 81    | 4830                | 105         | 34.2762                  | 3.6892           |
| year                                                                   | 2       | 81    | 10295               | 200         | 24.045                   | 2.588            |
| Acet2                                                                  | 1       | 77    | 2950                | 82          | 20.3049                  | 2.1854           |
| Acute Respiratory Distress Syndrome                                     | 1       | 81    | 5067                | 127         | 26.063                   | 2.8052           |
| Addition                                                               | 1       | 81    | 3290                | 89          | 3.7528                   | 0.4093           |
| Admission                                                              | 2       | 81    | 11509               | 227         | 10.6123                  | 1.1422           |
| age                                                                    | 3       | 81    | 11724               | 226         | 17.2522                  | 1.6812           |
| April                                                                  | 5       | 81    | 6073                | 121         | 6.3471                   | 0.6831           |
| Ards                                                                   | 1       | 77    | 4060                | 102         | 12.5294                  | 1.3486           |
| article                                                                | 1       | 81    | 4303                | 122         | 4.4016                   | 0.4738           |
| Association                                                            | 3       | 81    | 5055                | 93          | 30.5484                  | 3.2987           |
| care                                                                   | 4       | 81    | 9407                | 281         | 5.0641                   | 0.5468           |
| case                                                                   | 5       | 81    | 21451               | 555         | 12.6649                  | 1.364            |
| child                                                                  | 5       | 81    | 4932                | 151         | 4.0464                   | 0.4355           |
| china                                                                  | 2       | 81    | 7650                | 172         | 25.407                   | 2.7346           |
| Clinical Characteristic                                                | 2       | 81    | 4076                | 77          | 32.6104                  | 3.5099           |
| Comorbidity                                                            | 3       | 81    | 8449                | 178         | 19.7584                  | 2.1349           |
| Complication                                                           | 1       | 81    | 43447               | 1196        | 9.8712                   | 1.0629           |
| Coronavirus                                                            | 1       | 81    | 7972                | 232         | 15.3578                  | 1.6551           |
| Coronavirus Disease                                                    | 1       | 81    | 19632               | 498         | 18.998                   | 2.0448           |
| country                                                                | 4       | 81    | 4056                | 106         | 10.958                   | 1.0703           |
| covid                                                                  | 1       | 81    | 136572              | 3972        | 10.1803                  | 1.0958           |
| Cytokine Storm                                                         | 1       | 78    | 2548                | 81          | 5.9012                   | 0.6352           |
| data                                                                   | 5       | 81    | 14373               | 294         | 15.0272                  | 1.6174           |
| day                                                                    | 2       | 81    | 10004               | 215         | 17.8326                  | 1.9193           |
| death                                                                  | 3       | 81    | 11838               | 237         | 16.8608                  | 1.8148           |
| December                                                               | 2       | 81    | 3254                | 81          | 21.679                   | 2.3333           |
| diabetes                                                               | 3       | 81    | 7891                | 173         | 6.948                    | 0.7478           |
| diabetes                                                               | 3       | 79    | 5683                | 89          | 6.1461                   | 0.6615           |
| diagnosis                                                              | 5       | 81    | 6494                | 157         | 8.9873                   | 0.9673           |
| disease                                                                | 1       | 81    | 29238               | 761         | 11.2943                  | 1.2156           |
| drug                                                                   | 1       | 81    | 5427                | 144         | 8.0764                   | 0.8693           |
| effect                                                                 | 1       | 81    | 8792                | 222         | 9.4324                   | 1.0152           |
| evidence                                                               | 1       | 81    | 8986                | 241         | 11.1452                  | 1.1996           |
| fever                                                                  | 5       | 81    | 4561                | 108         | 18.3796                  | 1.9782           |
| group                                                                  | 2       | 81    | 11325               | 222         | 11.8288                  | 1.2732           |
| Higher Risk                                                            | 3       | 81    | 3236                | 73          | 17.8356                  | 1.9197           |
| hospital                                                               | 2       | 80    | 9604                | 180         | 16.0056                  | 1.7254           |
| hospitalization                                                        | 2       | 81    | 4762                | 95          | 24.3789                  | 2.6239           |
| hypertension                                                           | 3       | 81    | 5960                | 111         | 21.8739                  | 2.5643           |
| icu                                                                    | 2       | 79    | 3409                | 69          | 11.2174                  | 1.2075           |
| impact                                                                 | 4       | 81    | 6252                | 164         | 10.7988                  | 1.1685           |
| incidence                                                              | 2       | 81    | 5196                | 102         | 10.3922                  | 1.1185           |
| individual                                                             | 3       | 81    | 3734                | 97          | 6.5773                   | 0.713            |
| infection                                                              | 1       | 81    | 36677               | 970         | 10.2999                  | 1.1339           |
| Intensive Care Unit                                                   | 2       | 81    | 5042                | 109         | 10.7339                  | 1.1598           |

(Continued)
| Keywords                                | cluster | Links | Total link strength | Occurrences | Average publishing years | Average citations |
|----------------------------------------|---------|-------|---------------------|-------------|--------------------------|-------------------|
| Level                                  | 2       | 81    | 11449               | 280         | 28.3036                  | 3.0464            |
| Management                             | 4       | 81    | 11873               | 314         | 6.9841                   | 0.7548            |
| March                                  | 2       | 80    | 7026                | 142         | 8.0845                   | 0.8701            |
| Mortality                              | 3       | 81    | 18373               | 363         | 18.1488                  | 1.9547            |
| Need                                   | 4       | 81    | 4283                | 126         | 7.5635                   | 0.8114            |
| Number                                 | 4       | 81    | 7299                | 170         | 8.6294                   | 0.9317            |
| Obesity                                | 3       | 80    | 4120                | 89          | 4.382                    | 0.4716            |
| Outbreak                               | 4       | 81    | 7508                | 162         | 20.1605                  | 2.1699            |
| Outcome                                | 3       | 81    | 20998               | 417         | 16.8585                  | 1.8157            |
| Pandemic                               | 4       | 81    | 21700               | 619         | 5.2763                   | 0.5687            |
| Patient                                | 2       | 81    | 125336              | 3249        | 16.9471                  | 1.8251            |
| Person                                 | 3       | 81    | 7936                | 190         | 5.5632                   | 0.5988            |
| Pneumonia                              | 5       | 81    | 8778                | 216         | 13.3704                  | 1.4391            |
| Pregnancy                              | 5       | 80    | 5430                | 114         | 19.5088                  | 2.0998            |
| Pregnant Woman                         | 5       | 79    | 4581                | 102         | 13.4314                  | 1.4456            |
| Recommendation                         | 4       | 80    | 4012                | 116         | 7.9224                   | 0.8527            |
| Report                                 | 5       | 81    | 7448                | 193         | 14.399                   | 1.5523            |
| Review                                 | 1       | 81    | 12982               | 327         | 7.2263                   | 0.7778            |
| Risk                                   | 4       | 81    | 18852               | 490         | 9.4224                   | 1.0182            |
| Risk Factor                            | 3       | 81    | 7551                | 152         | 9.0724                   | 0.9765            |
| Role                                   | 1       | 81    | 5383                | 171         | 3.6433                   | 0.3921            |
| Sars Cov                               | 1       | 81    | 36063               | 1028        | 9.2091                   | 0.9926            |
| Severe Acute Respiratory Syndrome      | 1       | 81    | 8304                | 232         | 13.431                   | 1.4477            |
| Severe Covid                           | 1       | 81    | 4092                | 103         | 6.0485                   | 0.651             |
| Severity                               | 3       | 81    | 6534                | 139         | 11.0504                  | 1.1894            |
| Study                                  | 2       | 81    | 32033               | 665         | 12.8307                  | 1.381             |
| Surgery                                | 4       | 78    | 10541               | 234         | 7.6325                   | 0.8215            |
| Symptom                                | 5       | 81    | 13853               | 352         | 12.054                   | 1.2974            |
| Time                                   | 2       | 81    | 9549                | 231         | 13.8701                  | 1.4971            |
| Total                                  | 2       | 80    | 3852                | 77          | 16.6883                  | 1.7962            |
| Treatment                              | 1       | 81    | 19442               | 521         | 8.3129                   | 0.8985            |
| Type                                   | 3       | 81    | 5512                | 96          | 10.0417                  | 1.0608            |
| Use                                    | 1       | 81    | 5959                | 154         | 9.3247                   | 1.0068            |
| Virus                                  | 1       | 81    | 8190                | 234         | 9.3761                   | 1.0092            |
| Week                                   | 5       | 79    | 3737                | 74          | 26.8649                  | 2.8915            |
| World                                  | 4       | 81    | 2941                | 84          | 6.6071                   | 0.717             |
| Wuhan                                  | 2       | 81    | 4830                | 105         | 34.2762                  | 3.6692            |
| Year                                   | 2       | 81    | 10295               | 200         | 24.045                   | 2.588             |
| Aces2                                  | 1       | 77    | 2950                | 82          | 20.3049                  | 2.1854            |
| Acute Respiratory Distress Syndrome    | 1       | 81    | 5067                | 127         | 26.063                   | 2.8052            |
| Addition                               | 1       | 81    | 3290                | 89          | 3.7528                   | 0.4039            |
| Admission                              | 2       | 81    | 11509               | 227         | 10.6123                  | 1.1422            |
| Age                                    | 3       | 81    | 11724               | 226         | 17.2522                  | 1.8612            |
| April                                  | 5       | 81    | 6073                | 121         | 6.3471                   | 0.6831            |
| Ards                                   | 1       | 77    | 4060                | 102         | 12.5294                  | 1.3486            |
| Article                                | 1       | 81    | 4303                | 122         | 4.4016                   | 0.4738            |
| Association                            | 3       | 81    | 5055                | 93          | 30.5484                  | 3.288             |
| Care                                   | 4       | 81    | 9407                | 281         | 5.0641                   | 0.5468            |
| Case                                   | 5       | 81    | 21451               | 555         | 12.6649                  | 1.364             |
| Child                                  | 5       | 81    | 4932                | 151         | 4.0464                   | 0.4355            |
| China                                  | 2       | 81    | 7650                | 172         | 25.407                   | 2.7346            |
| Clinical Character                     | 2       | 81    | 4076                | 77          | 32.6104                  | 3.5099            |
| Comorbidity                            | 3       | 81    | 8449                | 178         | 19.7584                  | 2.1349            |
| Complication                           | 1       | 81    | 43447               | 1196        | 9.8712                   | 1.0629            |
| Coronavirus                            | 1       | 81    | 7972                | 232         | 15.3578                  | 1.6551            |
| Coronavirus Disease                    | 1       | 81    | 19632               | 498         | 18.998                   | 2.0448            |
| Country                                | 4       | 81    | 4056                | 108         | 10                      | 1.0762            |
| Covid                                  | 1       | 81    | 136572              | 3972        | 10.1803                  | 1.9558            |
| Cytokine Storm                         | 1       | 78    | 2548                | 81          | 5.9012                   | 0.6352            |
| Data                                   | 5       | 81    | 14373               | 294         | 15.0272                  | 1.6174            |
| Day                                    | 2       | 81    | 10004               | 215         | 17.8326                  | 1.9193            |
| Death                                  | 3       | 81    | 11838               | 237         | 16.8608                  | 1.8148            |
| December                               | 2       | 81    | 3254                | 81          | 21.679                   | 2.3333            |

(Continued)
revealed that more than half of patients had gastrointestinal reactions (14). In addition, in a retrospective analysis of clinical cases, it was reported that 27.3% of patients showed liver biochemistry abnormalities and 3.9% had liver injury (61). The disturbance of the digestive system is attributed to the expression of ACE2 and the ACE2 receptor in digestive ducts (62, 63). The pathogenesis is similar to the complication experienced in the cardiovascular systems. However, most of the gastrointestinal complication caused by COVID-19 disappeared after effective treatment of the pneumonia, with few obvious sequelae. In addition, more noteworthy was the role of intestinal flora in the development of COVID-19. On the one hand, clinical data indicated the intestinal flora was disordered in patients with COVID-19, which lead to the adverse reactions in the gastrointestinal tract (64, 65). On the other hand, the intestinal flora had the potential to promote the activity of anti-inflammation cells in the alveolar and inhibit the progression of pneumonia, which is defined as the “gut-lung axis” (66).

**Urinary Complication**

The kidney is one of the important target organs causing the high mortality rate of COVID-19 (67). A clinical study entitled “Caution on Kidney Dysfunctions of 2019-nCoV Patients” published on the preprint platform medRxiv stated that 63% of patients showed symptoms of renal insufficiency, and CT scans showed 100% of patients with renal imaging abnormalities. It has been noted that kidney involvement in COVID-19 is frequent and it ranges from mild proteinuria to acute kidney injury (AKI) (68, 69). Numerous studies have indicated a high incidence of AKI in patients with COVID-19, especially in severe cases (70–72). According to clinical statistics, the mortality rate of COVID-19 patients with AKI was three times higher than in patients without kidney injury (73). Microscopic observation of the kidneys of patients who died of COVID-19 found that most patients had obvious renal tubular damage (74). Acute kidney injury significantly contributes to long-term effects on the kidney, such as microalbuminuria and chronic kidney diseases or renal failure, which needs routine dialysis (75). However, no studies have been reported on the long-term renal outcomes among patients recovered from COVID-19 (76). Therefore, it is essential to monitor the renal function of patients who are discharged from the hospital, especially with kidney damage caused by coronaviruses infection in order to improve the prognosis of COVID-19 and to prevent further renal injuries. The kidney injury was more due to the secondary effect of immune reactions induced by 2019-nCoV rather than any direct effect of the virus (77). In other words, although COVID-19 could invade the kidney cells through the ACE2-dependent pathway, the virus-associated immune response and cytokine secretion were more likely to attack normal cells and cause kidney damage (78). However, this is based on only a consensus of the majority, and the pathogenesis of COVID-19 in kidney damage is still inconclusive. Identifying the reason for the kidney alterations will contribute to increased efficiency of treatment and an improved prognosis.

**Endocrine Complication**

In terms of the clinical manifestations of patients with COVID-19, most endocrine glands might be affected by the virus, such as the pancreas, adrenal glands, thyroid, etc. (79). Recent studies
FIGURE 6 | Keywords in publications about COVID-19 complication and sequelae research. (A) Mapping of the keywords into seven clusters with different colors. (B) Distribution of keywords was presented according to the appearance for the average time.
have indicated that patients with a history of diabetes were more susceptible to 2019-nCoV (80, 81). In addition, the presence of diabetes mellitus increased the risk of requiring critical care (82, 83). It was found in a microscope observation of the adrenal glands of patients with COVID-19 that 46% showed alterations in adrenal gland morphology such as ischemia, hemorrhage, degeneration, and local inflammation (84). Adrenal vascular alterations are likely to be caused by the immune disorder induced by 2019-nCoV (85). In addition, 15% of patients with COVID-19 had thyroid dysfunction (86). This was also attributed to the immunity response and autoimmunity induced by 2019-nCoV (87, 88). Meanwhile, the outbreak of the COVID-19 epidemic might worsen some glandular tumors and delay the timing of treatment (89). The above evidence showed that 2019-nCoV could attack the glands via the immune system, which might be the entry point for the treatment of endocrine complication. If there is no effective treatment, it will further aggravate the condition of diabetes and increase the risk of cancer and other chronic endocrine diseases.

**Reproductive Complication**

There are obvious sex differences in reproductive complication and sequelae. Recent studies had confirmed ACE2 is abundant in gametocytes, Sertoli cells and spermatogonia stem cells, suggesting the testis is a high-risk organ vulnerable to 2019-nCoV infection (90, 91). Indeed, coronavirus could damage the structure of the testicles and affect male fertility, supported by the detection of coronavirus in the semen of patients, some of whom had complication of orchitis (92). An observational study indicated that 39.1% of male patients with COVID-19 have oligospermia and 60.9% of them have a high inflammatory state in their semen (93). Around 19% of patients at the time of their COVID-19 confirmation were experiencing scrotal discomfort (94). In addition, interstitial oedema and congestion in the testes and epididymis are observed in all deceased COVID-19 patients, which also indicate potential testis injury (93). Compared with male patients, there are relatively few reports on the impact of the coronavirus on the female reproductive system. However, ACE2 has been demonstrated to be widely expressed in the female genital tract and ovary (95, 96), and thereby is likely to affect ovulation and embryonic development in a similar way (97, 98). Due to a lack of attention and limited duration of hospitalization, other reproductive dysfunctions such as infertility and menstrual disorders are difficult to identify. Therefore, follow-up studies and evaluation of reproductive function, especially fertility, is essential among patients recovered from COVID-19.

**Skeletal Complication**

During the epidemic of SARS, myalgia and muscle weakness were common complication (99). COVID-19 also has a direct impact on the skeletal system together with an indirect action through the regulation of nerves and the blood supply. 2019-nCoV combines with ACE2 and destroys the balance of RAS, which causes degradation of muscle protein and leads to physical dysfunction (100). In addition, infection-mediated deleterious immune responses lead to neurological abnormalities, and a significant increase in serum pro-inflammatory cytokines may lead to skeletal muscle damage (101). In addition, patients with myalgia tend to have higher levels of creatine kinase and lactate dehydrogenase (12). Elevated levels of the pro-inflammatory factor interleukin-6 may be responsible for the myalgia and joint pain (102). Osteoimmunology reveals the potential effect of viral infection on the RANK-RANKL system, which increases bone resorption and induces osteoporosis. It is worth noting that after being discharged from the hospital, severe patients may have sequelae of muscle wasting due to the prolonged period spent in bed, and they require progressive rehabilitation training to gradually return to their pre-onset mobility (103). Furthermore, severe patients treated with glucocorticoids may also experience hip joint injuries and femoral head necrosis (104). At present, it seems that the patient’s condition is not effectively controlled, and an overdose of glucocorticoids is given, which may cause sequelae such as osteoporosis and osteonecrosis.

**Other Involvement: Psychological Changes**

The influence of COVID-19 on mental health due to restricted activity in public should not be ignored. The mental health status reported by patients with COVID-19 appears to be more serious. They fear death and are very prone to negative emotions (105). Unlike SARS survivors, the incidence of depression, anxiety, insomnia, and acute stress in patients with COVID-19 is 75%, 71%, 68%, and 71%, respectively, while the incidence of mental and psychological problems in COVID-19 survivors, 3 months after discharge and 30 months after discharge, is also much higher.

There are two aspects to the psychological complication or sequelae caused by COVID-19. One is that severely ill patients have experienced the fear of death. Even if their bodies recover, some people still have psychological fears. The other is that patients with mild illnesses cause people to fear rejection by others after their recovery. Many people who have recovered from mild illness have nervousness, anxiety, and fear. Regardless of whether they had mild or severe cases, nearly half of survivors have post-traumatic stress disorder, depression, or insomnia and anxiety. Some people cannot return to a normal state.

The mental and psychological problems of medical staff are even more prominent, and the incidence is significantly higher than that of non-medical staff. Among them, nurses have the highest incidence of psychological problems. It is indicated that anxiety among medical staff is 46%, while the incidence among non-medical staff is 8.5%. Other people, including front-line workers and their families, close contacts, and people in isolation, as well as low-income people in the community, are also susceptible to psychological problems, indicating that ordinary citizens also experience poor psychological health in the epidemic. It is shown that in the first five months of the pandemic, Japan’s monthly suicide rate dropped by 14%, but it rose by 16% in the second wave 90, while the suicide rate of women, children, and adolescents has increased even more.

Therefore, in the post-epidemic era, the construction of a mental health system is particularly important. A grid-based community psychological service system should be established, especially in the prevention stage. For example, a three-person
psychological service team should be formed in schools, communities and some medical units to screen and serve for the mental health of the population. In addition, mental and psychological education courses should also be introduced in primary and secondary schools to avoid impairments of the mental development of the students.

As is mentioned above, clinical complications and sequelae of COVID-19 were common among survivors during early convalescence. Apart from the clinical characteristics during hospitalization, the outcomes of COVID-19 also vary across different ages and ethnic backgrounds. It was observed in a large cohort of survivors of COVID-19 in Wuhan, China that survivors with old age are especially susceptible to complications or sequelae of COVID-19 compared with younger individuals (106). Indeed, ageing plays an important role in the development of COVID-19 and its complications or sequelae. With age, mitochondrial quality, and function declines, leading to a variety of physiology changes, such as chronic inflammation and defective immune responses to viral infection, which eventually increases the susceptibility to COVID-19 complications and sequelae (107, 108). Likewise, the outcomes of COVID-19 also present certain ethnic and racial differences. It was observed that black patients with COVID-19 usually had higher mortality rates that white patients, which was also noted among pediatric patients. However, the racial disparities are more like to be multifactorial while black race alone was not associated with the high mortality rates (109–111). Black patients had higher prevalence of chronic diseases, such as diabetes, hypertension, chronic renal diseases and so forth. As is mentioned above, patients with pre-existing diseases usually had bad poor clinical outcomes and were with higher risks of various complications and sequelae. Additionally, work environment, living conditions, public insurance and economic conditions were also responsible for the prevalence and mortality rate of COVID-19 (110).

Currently, no specific treatment targeting major complications and sequelae of COVID-19, which is only limited to symptomatic treatment. Additionally, there is even no effective therapy for complications in certain systems, such as the reproductive system. Therefore, current treatment options should be extended in patients with COVID-19 and personalized therapies should be implemented based on the clinical characteristics during hospitalization and also the individual circumstances, such as age and pre-existing diseases. Consequently, it is crucial to development reasonable and effective treatment strategies to restore function of organs which were damaged during the course of COVID. In addition, daily symptom monitoring is necessary for patients discharged from hospital. Routine physical examination is strongly recommended for severe or elderly patients and patients with pre-existing diseases until 6 months after discharge.

There are several limitations that are specific to the use of bibliometric analysis in this study which may be inevitable. It has been only less than two years since the outbreak of COVID-19. Although significant breakthroughs have been made in the understanding COVID-19, there are relatively few literatures focused on the complications and sequelae of COVID-19 that have been published. As a result, only 82 keywords were extracted from the published literatures, which may lead to the inaccuracies in the classification of keywords. In addition, with accumulating evidence indicating that many survivors of COVID-19 are suffered from various complications and sequelae, it is believed that growing numbers of studies will focus on the complications and sequelae of COVID-19. Therefore, there may be discrepancies between our bibliometric analysis and the actual publication situation.

CONCLUSIONS

In the context of vaccination and effective medications, there are no obstacles to the elimination of 2019-nCoV. However, the damage of 2019-nCoV to the body has been ignored. We systematically analyzed the complication and sequelae of the eight systems of COVID-19 patients. Most of the complication or sequelae of patients are related to the expression of ACE2 on tissues and organs, which is the target recognized and bound by 2019-nCoV. The RAS axis participates in the regulatory process and leads to systemic disorders when the axis feedback is imbalanced. At the same time, we analyzed various psychological barriers of people in the post-epidemic era. In our study, we pay more attention to the adverse variations to the body caused by 2019-nCoV rather than just the virus itself. In conclusion, the prevention and treatment of complications and sequelae in COVID-19 patients in the post-epidemic era are the top priority, and they should and must attract the close attention of experts and scholars around the world.

AUTHOR CONTRIBUTIONS

Conceptualization: LT, KY, JW, and GW. Methodology: KY, GW, and SZ. Investigation: LT, KY, GW, JW, SZ, WD, YM, and YX. Writing – original draft: KY, GW, JW, SZ, WD, YM, and YX. Writing – review and editing: LT, KY, JW, and GW. Supervision: LT, KY, JW, and GW. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the fellowship of China Postdoctoral Science Foundation [2020M670100ZX].

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.711741/full#supplementary-material

Supplementary Figure 1 | Flow chart of literature filtering involved in this study.

Supplementary Figure 2 | Complication and sequelae of COVID-19 patients involved in eight major systems.
REFERENCES

1. Moore B, Lee P, Hewish M, Dixon B, Mukherjee T. Coronaviruses in Training Centre for Intellectually Retarded. Lancet (London England) (1977) 1:261. doi: 10.1016/S0140-6736(77)91064-9

2. Tao Z, Zhao S, Tao R, Wen K, Da W, Meng Y, et al. COVID-19 Will Stimulate a New Coronavirus Research Breakthrough: A 20-Year Bibliometric Analysis. Ann Trans Med (2020) 8:528. doi: 10.21037/ atm.2020.04.26

3. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A New Coronavirus Associated With Human Respiratory Disease in China. Nature (2020) 579:265–9. doi: 10.1038/s41586-020-00803

4. Jamwal S, Gautam A, Elsworth J, Kumar M, Chawla R, Kumar P. An Updated Insight Into the Molecular Pathogenesis, Secondary Complications and Potential Therapeutics of COVID-19 Pandemic. Life Sci (2020) 257:118105. doi: 10.1016/j.lfs.2020.118105

5. Beghi E, Helbok R. The EAN COVID-19 Registry (ENERGY): An International Instrument for Surveillance of Neurological Complications in Patients With COVID-19. Euro J Neurol (2020). doi: 10.1111/ene.14652

6. Zahra W, Dixon JW, Mirtorabi N, Roltin DJ, Tayton ER, Hale PC, et al. Safety Evaluation of a Strategy to Restart Elective Orthopaedic Surgery During the De-Escalation Phase of the COVID-19 Pandemic. Bone Joint Open (2020) 1:450–6. doi: 10.1302/2633-1462.18.BJO-2020-0105.R1

7. Huang C, Huang L, Wang Y, Li X, Ren L, Gu D, et al. 6-Month Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. N Engl J Med (2020) 382:2302. doi: 10.1056/NEJMoa2015432

8. Varshney AS, Al-Shehayleh A, Alabdulwahab A, Qari S, Siddiqi HK, et al. Characteristics of Clinical Trials Evaluating Cardiovascular Therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: A Cross Sectional Analysis. Am Heart J (2020) 232:105–13. doi: 10.1016/j.ahj.2020.10.056

9. Caviedel C, Weiss L, Haag L, Habeker M, Varga Z, et al. Case Report of Sequential Bilateral Spontaneous Pneumothorax in a Never-Ventilated, Lung-Healthy COVID-19-Patient. Int J Surg Case Rep (2020) 75:441–5. doi: 10.1016/j.jsrcr.2020.09.148

10. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Weite L, Taenger F, et al. Pulmonary Vascular Endotheliolysis, Thrombosis, and Angiogenesis in Covid-19. New Engl J Med (2020) 383:120–8. doi: 10.1056/NEJMoa2015432

11. Scholkmann F, Nicholls J. Pulmonary Vascular Pathology in Covid-19. New Engl J Med (2020) 383:887–8. doi: 10.1056/NEJMct2022068

12. Yang ZL, Chen C, Huang L, Zhou SC, Hu YN, Xia LM, et al. Fibrotic Changes Depicted by Thin-Section CT in Patients With COVID-19 at the Early Recovery Stage: Preliminary Experience. Front Med (2020) 7:605088. doi: 10.3389/fmed.2020.605088

13. Ilic I, Zdravkovic M, Timsic S, Stojanovic DU, Bojic M, Loncar G. Pneumonia in Medical Professionals During COVID-19 Outbreak in Cardiovascular Hospital. Int J Infect Dis (2020) 103:188–93. doi: 10.1016/j.ijid.2020.11.156.

14. Varshney AS, Al-Shehayleh A, Alabdulwahab A, Qari S, Siddiqi HK, et al. Characteristics of Clinical Trials Evaluating Cardiovascular Therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: A Cross Sectional Analysis. Am Heart J (2020) 232:105–13. doi: 10.1016/j.ahj.2020.10.056

15. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol (2020) 5:802–10. doi: 10.1001/jamacardio.2020.0950

16. Li X, Pan X, Li Y, An N, Xing Y, Yang F, et al. Cardiac Injury Associated With Severe Disease or ICU Admission and Death in Hospitalized Patients With COVID-19: A Meta-Analysis and Systematic Review. Crit Care (London England) (2020) 24:248. doi: 10.1186/s13054-020-03183-z

17. Naboros C, Sridhar A, Hooda U, Lobo SA, Levine A, Frishman WH, et al. Fibrotic Changes Depicted by Thin-Section CT in Patients With COVID-19 at the Early Recovery Stage: Preliminary Experience. Front Med (2020) 7:605088. doi: 10.3389/fmed.2020.605088

18. Keri VC, Hooda A, Kodan P, Brunda RL, Jorwal P, Wig N. Intricate Interplay Between Covid-19 and Cardiovascular Diseases. Rev Med Virol (2020) 31(4):e2188. doi: 10.1002/rmv.2188

19. Wen W, Zang H, Zhou M, Cheng Y, Ye L, Chen J, et al. Arrhythmia in Patients With Severe Coronavirus Disease (COVID-19): A Meta-Analysis. Eur Rev Med Pharmacol Sci (2020) 24:11395–401.
86. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, et al. Thyroiditis Might Be a Complication Triggered by SARS-CoV-2. Diagn Histopathol (2020) 106(2):e926–35. doi: 10.1016/j.dhpm.2020.09.002.

87. Ruano R, Zorzano-Martinez M, Campos A, Rius F, Hernandez M, et al. Adrenal Vascular Changes in COVID-19 Autopsies. Arch Pathol Lab Med (2020) 144:1159–60. doi: 10.5858/apra.2020-0248-LE.

88. Freire Santana M, Borba MGS, Baia-da-Silva DC, Val F, Alexandre MAA, Brito-Sousa JD, et al. Case Report: Adrenal Pathology Findings in Severe COVID-19: An Autopsy Study. Am J Trop Med Hyg (2020) 103:1604–7. doi: 10.4269/ajtmh.20-0787.

89. Iuga AC, Marboe CC, Yilmaz MM, Lefkowitch JH, Gauran C, Lagana SM. Angiotensin-(1-7), its Receptor Mas , and the Angiotensin-Converting Enzyme Type 2 Are Expressed in the Human Ovary. Fertil Steril (2011) 95:1756–81. doi: 10.1016/j.fertnstert.2010.06.060

90. Gonzalez A, Orozco-Aguilar J. SARS-CoV-2-Renin-Angiotensin System: Deciphering the Clues for a Couple With Potentially Harmful Effects on Skeletal Muscle. Intern J Mol Sci (2020) 21:7904. doi: 10.3390/ijms21217904.

91. Ali FF, Ahmed AF, Elroby Ali DM. Underlying Mechanisms Behind the Ischemia Reperfusion Injury. J Endocrinol Invest (2020) 43:1153–7. doi: 10.1007/s13410-020-00888-3.

92. Corona G, Baldi E. SARS-CoV-2 Infection, Male Fertility and Sperm Cryopreservation: A Position Statement of the Italian Society of Andrology and Sexual Medicine (SIAMS) (Società Italiana Di Andrologia E Medicina Della Sexualità). J Endocrinol Invest (2020) 23:8357–r374. doi: 10.1530/ERC-20-0229.

93. Li H, Xiao A, Zhang J, Zafar MI, Wu C, Long Y, et al. Impaired Spermatogenesis in COVID-19 Patients. EClinMedicine (2020) 28:100604. doi: 10.1016/j.eclinm.2020.100604.

94. Pan F, Xiao X, Guo J, Song Y, Li H, Patel DP, et al. No Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 in Semen of Males Recovering From Coronavirus Disease 2019. Fertil Steril (2020) 113:1135–9. doi: 10.1016/j.fertnstert.2020.04.024.

95. Asch DA, Islam MN, Shels NE, Chen Y, Doshi JA, Buresh J, et al. Patient and Hospital Factors Associated With Differences in Mortality Rates Among Black and White US Medicare Beneficiaries Hospitalized With COVID-19 Infection. JAMA Net Open (2021) 4:e2112842. doi: 10.1001/jamanetworkopen.2021.12842.

96. Price-Haywood EG, Burch J, Fort D, Seone L. Hospitalization and Mortality Among Black Patients and White Patients With Covid-19. New Engl J Med (2020) 382:2354–43. doi: 10.1056/NEJMsa2011686.

97. Jing Y, Run-Qian L, Hao-Ran W, Hao-Ran C, Ya-Bin L, Yang G, et al. Potential Influence of COVID-19/ACE2 on the Female Reproductive System. Mol Hum Reprod (2020) 26:367–73. doi: 10.1093/molehr/gaa030.

98. Yang Y, Chen S, Tian H, Liu Y, Liu Y, et al. COVID-19 Pandemic. Am J Trop Med Hygien (2020) 103:1604. doi: 10.4081/monaldi.2020.1507.

99. Ali FF, Ahmed AF, Elroby Ali DM. Covid-19 and Kidney Injury: Pathophysiology and Molecular Mechanisms. Rev Med Virol (2020) p. e12176. doi: 10.1002/rmv.2176.

100. Gonzalez A, Orozco-Aguilar J. SARS-CoV-2/Reinin-Angiotensin System: Deciphering the Clues for a Couple With Potentially Harmful Effects on Skeletal Muscle. Intern J Mol Sci (2020) 21:7904. doi: 10.3390/ijms21217904.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Yang, Wen, Wang, Zhou, Da, Meng, Xue and Tao. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.